Jade Biosciences, Inc.(JBIO)Earnings, Financials & Key RatiosJade Biosciences, Inc. (JBIO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's current cash burn rate of over $40M per quarter relative to its $55.1M cash balance suggests significant near-term dilution risk for existing shareholders.
Jade Biosciences, Inc. (JBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Jade Biosciences, Inc. (JBIO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.57vs $0.52-9.6% | — |
| Q2 2026 | Mar 6, 2026 | $0.11vs $0.45+75.6% | — |
| Q4 2025 | Nov 13, 2025 | $0.48vs $0.57+15.8% | — |
| Q3 2025 | Aug 13, 2025 | $0.86vs $0.43-100.0% | — |
Recent stock market news and headlines for Jade Biosciences, Inc. (JBIO)
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026.
Key metrics vs top competitors for Jade Biosciences, Inc. (JBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.00 | $717.77M | -5.42 | — | — | -62.31% | — | |
| $372.25 | $10.97B | 54.42 | 33.94% | 53.92% | 19.25% | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $27.00 | $3.38B | -207.69 | 91.34% | -0.57% | -1.41% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — |
Jade Biosciences, Inc. (JBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when JBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Jade Biosciences, Inc. (JBIO) stock FAQ — growth, dividends, profitability & financials explained
Jade Biosciences, Inc. (JBIO) reported a net loss of $129.6M for fiscal year 2025.
Jade Biosciences, Inc. (JBIO) has a return on equity (ROE) of -62.3%. Negative ROE indicates the company is unprofitable.
Jade Biosciences, Inc. (JBIO) had negative free cash flow of $116.6M in fiscal year 2025, likely due to heavy capital investments.
